FocalTherics (FOCL) Q2 2026 earnings review
Strategic Pivot to HIFU Yields 39% Growth, But Cash Burn Triggers $40M Raise
FocalTherics officially cut the cord on its legacy ESWL and Distribution segments, moving them to discontinued operations to go all-in on the Focal One platform. The top-line results validate this focus: continuing operations revenue grew 39% YoY to $13.2M, driven by 13 system placements and a 47% surge in U.S. procedures. Better production absorption pushed gross margins up to an impressive 55.6%. However, the cost of this growth is steep. Operating expenses jumped to $15.4M, widening the operating loss to $8.0M. Combined with a heavy $5.5M non-cash warrant charge, net losses hit $14.4M, forcing management to announce a $40M public equity offering to fund ongoing commercial expansion.
🐂 Bull Case
By shifting the declining, lower-margin ESWL and Distribution businesses into discontinued operations, the financial statements now reflect a pure-play, high-growth robotics company.
U.S. procedure volumes grew 47% YoY, indicating that previously placed systems are being heavily utilized, establishing a foundation for high-margin, recurring consumable revenue.
🐻 Bear Case
Despite ending the quarter with $21.5M in cash, the widening losses necessitated a $40M underwritten public offering, which will immediately dilute existing shareholders.
Operating expenses jumped 34% YoY to $15.4M. The company is burning significant cash to achieve its top-line growth, and operating leverage is not yet materializing.
⚖️ Verdict: ⚪
Neutral. The underlying business metrics (system placements, procedure growth, gross margin) are excellent and the portfolio cleanup is welcome. However, the widening operating losses and the immediate dilutive impact of a $40M equity raise cap near-term upside.
Key Themes
The End of the Legacy Drag
The most significant structural change this quarter is the reclassification of the ESWL and Distribution segments into discontinued operations. Previously, these segments acted as a persistent drag on consolidated growth and margins. Moving forward, FocalTherics' financials will solely reflect the high-growth HIFU business, making the company vastly easier for Wall Street to model and value as a pure-play medtech growth story.
System Placements and Procedure Volumes Surging
The core growth engine is firing on all cylinders. The company placed 13 Focal One systems globally (up from 9 in the prior year), expanding the total installed base to 184. Crucially, U.S. procedure volumes increased by 47% YoY. This dual momentum proves that the company is not just selling capital equipment, but successfully driving hospital utilization.
Gross Margin Expansion
HIFU gross margins expanded by 450 basis points to 55.6% from 51.1% a year ago. Management attributed this to improvements in the standard cost of the Focal One system and favorable overhead absorption due to higher production volumes. This indicates the manufacturing base is scaling efficiently.
Multi-Indication Expansion Begins in Earnest
FocalTherics launched its first commercial Focal One Endometriosis program in Europe (Toulouse University Hospital). This is a critical milestone, moving the technology beyond prostate cancer into a vastly larger Total Addressable Market (deep rectal endometriosis impacts an estimated 783,000 diagnosed patients globally).
Widening Operating Losses Outpace Revenue Growth
While revenue grew 39%, total operating expenses climbed 34% to $15.4M, resulting in a widened operating loss of $8.0M (up from $6.6M YoY). SG&A specifically jumped from $9.2M to $13.1M. While some of this included one-time rebranding costs ($0.8M), the core expense base is inflating rapidly, showing a lack of near-term operating leverage.
Dilution from Non-Cash Charges and Equity Raises
Below the operating line, the company absorbed a massive $5.5M non-cash loss regarding European Investment Bank (EIB) warrant valuations, crushing net income to -$14.4M. To sustain operations, management announced an immediate $40M public offering. Investors are paying a high dilutive price for the current growth trajectory.
U.S. Endometriosis Regulatory Uncertainty
While the European endometriosis launch is positive, the U.S. commercialization pathway remains a waiting game. As noted in prior quarters, the company is waiting on 24-month RCT data to negotiate with the FDA. Until a clear U.S. regulatory timeline is established, the near-term financial impact of the gynecology expansion will be limited to OUS markets.
Other KPIs
The U.S. footprint continues to scale rapidly, now making up over half of the 184 global systems. Demand is well balanced, with 44 academic centers and 52 community hospitals currently active, proving the technology appeals beyond just high-tier research institutions.
The Q2 SG&A expenses included approximately $800,000 in one-time costs associated with the corporate name change to FocalTherics, transitioning to a domestic filer, and executing the discontinued operations classification.
Guidance
Stable. The company reiterated its full-year guidance for the HIFU segment, implying 34% to 45% YoY growth. Achieving the $52M midpoint will require approximately $13.6M per quarter in H2, which is highly achievable given Q2's $13.2M print and the historical Q4 seasonal strength.
Key Questions
Path to Profitability
With the legacy businesses now cleanly separated into discontinued operations, what is the target timeline for the standalone HIFU business to reach operating cash flow breakeven?
Use of Proceeds
Beyond general working capital, how specifically will the $40M from the new public offering be deployed between U.S. commercial expansion and clinical R&D for new indications?
Endometriosis Revenue Contribution
Following the first commercial endometriosis program launch in Europe, how many pipeline systems are actively being evaluated primarily for gynecological use versus urology?